Celgene halts trial of blood cancer drug

Celgene said it will discontinue a Phase III study of its blood cancer treatment Revlimid as a first-line treatment in elderly patients with B-cell chronic lymphocytic leukemia after it noticed more deaths in patients treated with Revlimid compared with patients taking chlorambucil. The FDA put the study on clinical hold last week. Celgene said it will examine data from the trial to determine whether the imbalance is due to factors such as age or comorbidities.

View Full Article in:

Reuters · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA